Have you heard about Dealflow.eu’s Multicorporate Matchmaking activities?
We are bringing together EU-funded innovators and innovations with investment- and innovation-driven Corporates headquartered in the EU to foster collaboration on different levels, namely:
- Further technological development (open innovation),
- Piloting of products/solutions,
- Purchase of solutions by corporate (commercial relation),
- Investment relation.
The pitching innovators will:
- Get privileged access to European leading companies – a straightforward way to reach larger deals;
- Meet strategic partners and customers to validate disruptive solutions and accelerate market penetration;
- Collaborate with business-relevant counterparts on solutions that can best fit the market.
Multicorporate Matchmaking Event on Health & Medical Technologies
Together with the European Commission, Dealflow.eu will welcome a Multicorporate Matchmaking event on 6 November 2024. This event will join innovators with EU corporates dedicated to the Health & Medical Technology sector.
Are you an EU-funded innovator in the Health & Medical Technology sector? Apply here.
Are you an EU Corporate and are you interested in meeting the most promising EU-funded innovators at the next event? Express your interest here.
Meet the Corporates
CUF – Portugal
CUF is a leader in providing quality private healthcare services in Portugal, managing a network of hospitals, clinics, and an institute, totaling 31 healthcare units.
By combining digital tools, new ways of providing proximity care, and a larger, broader network of hospitals and clinics, CUF promotes specialized, differentiated, and personalized healthcare adapted to the needs of each person.
CUF’s mission is to promote the provision of healthcare services with the highest possible levels of quality and knowledge, prioritizing life and the environment, through the development of the intellectual capital of the organisations, in a continuous search for excellence.
In the development of its business, CUF relies on a strategic partnership with the National Association of Pharmacies, its shareholder.
SIEMENS Healthineers – Germany
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. As a leader in medical technology, they want to advance a world in which breakthroughs in healthcare create new possibilities with a minimal impact on our planet. By consistently bringing innovations to the market, they enable healthcare professionals to innovate personalized care, achieve operational excellence, and transform the system of care.
Their portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. With the unique combination of their strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), they are well positioned to take on the greatest challenges in healthcare. They will continue to build on these strengths to help overcome the world’s most threatening diseases, enable efficient operations, and expand access to care.
They are a team of more than 71,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.
Challenges for innovators
- Automation of clinical tasks and business support
- Ensure patient access to appropriate care in both urgent and scheduled journeys
- Promotion of health literacy using new technologies
- Improve the quality, speed, and standardization of diagnosis (support for clinical decision-making)
- New technologies for patient support throughout their journey (clinical and no clinical)
- Solutions to support diagnostics in CT, MR, X-Ray, Molecular Imaging or Ultrasound imaging (also multimodal)
- Workflow optimization for medical imaging (e.g. analysis, reporting)
- Solutions that support the vision of a Patient Digital Twin and clinical decision making
- LLM for Healthcare/MedTech
- Robotics for Healthcare (e.g. lab diagnostics, surgery)
- Innovative new lab tests for early diagnosis of non-communicable diseases
- Innovative offerings for new products or business models for decentralized patient testing (e.g. self-collected blood collection)
More about the Innovation Radar
The Innovation Radar is a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation projects. Its goal is to allow every citizen, public official, professional, and businessperson to discover the outputs of EU innovation funding and give them a chance to seek out innovators who could follow in the footsteps of companies such as Skype, TomTom, ARM Holdings, all of whom received EU funding in their early days.
To learn more about the Innovation Radar, visit https://www.innoradar.eu/
More about Dealflow.eu
Supported by the European Commission, Dealflow.eu discovers and supports the most promising EU-funded innovators and connects them with relevant investors and corporates. The initiative was launched to help ground-breaking innovations secure the funding needed for their future commercialisation by offering them tailored support and matchmaking services.
To learn more about Dealflow.eu, visit https://dealflow.eu/
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Directorate-General for Communications Networks, Content and Technology. Neither the European Union nor the granting authority can be held responsible for them.
